EuroPCR 2020 | Aortic Valve in Valve in the Long Term

The outcomes of this work are important to plan valve replacement with the largest possible prosthesis allowed by patient anatomy in the index procedure.

EuroPCR 2020 | Valve in Valve aórtico a largo plazo

As a worldwide trend, increasingly more patients are receiving bioprostheses, which have improved a lot but still tend to become deteriorated and require a valve-in-valve procedure if the patient is no longer a suitable candidate for surgery.

One of the main differences compared with conventional transcatheter aortic valve replacement is that valve-in-valve procedures tend to finish with residual gradient, which might affect the long-term durability of the prosthesis.

This work, presented at the virtual EuroPCR 2020 and simultaneously published in the European Heart Journal, analyzed 1006 valve-in-valve procedures from the VIVID registry. Mean patient age was 77.7 years old and the mean Society of Thoracic Surgeons (STS)-PROM score was 7.3%.

About half (52%) of patients received self-expanding valves (CoreValve or Evolut), and 43.2% received balloon-expandable prostheses of any generation (Sapien/Sapien XT/S3).


Read also: EuroPCR 2020 | FABOLUS FASTER: In the Quest for the Fastest, Most Potent Platelet Inhibition.


Survival at 8 years was 38% overall, but, comparing patients with small (internal diameter <20 mm) and large failed prostheses, survival was lower with smaller devices (33.2% vs. 40.5%; p = 0.01).

Smaller failed bioprostheses, age, lower ejection fraction, chronic kidney disease, diabetes, and nontransfemoral access were all independent predictors of mortality. The factors associated with reintervention were pre-existing severe patient prosthesis mismatch, device suboptimal implantation, age, and balloon-expandable valve use.

During the same EuroPCR session, researchers presented an update on the BASILICA registry. BASILICA is a technique that involves lacerating the preexisting aortic leaflet (native or failed prosthetic) with radiofrequency immediately before new prosthesis implantation in patients at high risk for coronary obstruction.


Read also: EuroPCR 2020 | Sudden Death Increase Two to Three Times While MI Rate Falls.


Now, the presentation reported 129 successful cases with the aforementioned procedure, including 22 cases of double BASILICA (both left- and right-sided leaflets were lacerated).

The technique was associated with a higher risk of stroke, compared with controls, but a lower risk of coronary obstruction and of 30-day mortality, stroke, and coronary obstruction, as a composite. The double BASILICA technique had a bad prognosis, as opposed to the laceration of a single leaflet.

valve-in-valve-ao-a-largo-plazo

Título original: Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves.

Presentador: Danny Dvir. Eur Heart J. 2020; Epub ahead of print y presentado en forma virtual en el EuroPCR 2020.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...